The pharmaceutical company’s third-quarter profit came in at $6.45 billion, or $7.22 a share, compared with $5.58 billion, or $6.21 a share, a year earlier.
Source link
About The Author
Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound